Drug Topics e-News:
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe. |
|
|
|
 |
Newest: Evolving pharmacy practice in the 21st century
|
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
|
Survey
|
|
This month we would like to know...
Approximately how much of your workday is spent dealing with insurance matters?
* 1/4 or less
* up to 1/3
* up to 1/2
* up to 2/3
* 3/4 or more
|
|
|
|
FDA limits acetaminophen in prescription combination products; requires liver toxicity warnings
FDA is asking manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 mg in each tablet or capsule. Read full article. |
|
|
DT Blog
|
A discussion generated by Drug Topics’ readers, editorial staff, and advisory board
David Stanley, RPh |
Patient Counseling: Walking a tightrope
Read full article.
|
|
Bristol-Myers Squibb recalls Avalide due to reduced effectiveness
Bristol-Myers Squibb Co. recently recalled 64 million tablets of Avalide blood pressure medication in the United States and Puerto Rico. Read full article. |
|
|
FDA: Severe liver injury associated with dronedarone use
Severe liver injury, including 2 cases of acute liver failure leading to liver transplant in patients treated with the medication, has been associated with the use of dronedarone (Multaq), according to an FDA Drug Safety Communication announcement. Read full article. |
|
|
FDA approves Abstral; REMs enrollment required
FDA has approved fentanyl (Abstral, ProStraken) transmucosal tablets to manage breakthrough pain for adults with cancer. Read full article.
|
|
|
|
Generic competition on the horizon as many pharmaceutical companies face patent expirations
The impact of generic drugs — which now account for more than 70% of all prescriptions dispensed in the United States — will continue to increase as some of the world’s most-prescribed products lose their patent protection in 2011 and begin facing generic competition. Read full article.
|
|
FDA OKs label update for etravirine
FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents. Read full article.
|
|
IDSA establishes guidelines to treat MRSA infections
The Infectious Diseases Society of America is set to release its first guidelines for the treatment of the increasingly common and potentially deadly methicillin resistant Staphylococcus aureus infection. Read full article.
|
|
HIV oral pre-exposure prophylaxis trial shows promise
The first trial to provide evidence that drugs used to treat HIV can also help to prevent HIV infection among men who have sex with men (when combined with other prevention strategies) was reported late November online in the New England Journal of Medicine. Read full article.
|
|
Meetings and Events
January 21-23, 2011 NCPA Diabetes Accreditation Standards-Practical Applications (DASPA)
Westin Gaslamp Quarter in San Diego
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
February 6-8, 2011 NACDS Regional Chain Conference
Naples, FL
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-837-4300
February 13, 2011 19th Annual WILLIAM R. BACON MEMORIAL Breakfast
6:30 a.m. - 8:45 a.m.
Palm Springs, CA
Contact:
800-333-7535; 760-325-6611
March 9-10, 2011 NACDS RxIMPACT Day on Capitol Hill
Washington, DC
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
hecker@nacds.org
March 13-15, 2011 NACDS Supply Chain & Logistics Conference
San Diego, CA
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678
March 25-28, 2011 American Pharmacists Annual Meeting
Seattle, WA
Contact:
2215 Constitution Avenue, NW
Washington, DC 20037
Phone: 1-800-237-2742 (APhA)
Fax: 202-448-8734
|
|
|
|
Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
